FDA OKs 'New-Gen' Antibiotic for Pneumonia, Skin Infections
The FDA approved omadacycline (Nuzyra) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Omadacycline is a semisynthetic derivative tetracycline antibiotic, specifically designed to overcome tetracycline resistance and proven to be effective across Gram-positive, Gram-negative, and other drug-resistant strains.

It has been nearly 20 years since the FDA approved a once-daily IV and oral antibiotic for the treatment of both CABP and ABSSSI, according to the release. The approval, which follows an FDA advisory committee recommendation in August, comes after more than two dozen clinical studies in this setting. The drug is expected to be available in the first quarter of 2019.

Read more here: https://pxmd.co/tp15V
Dr. V●●●k B●●●y J●●●n and 1 others like this5 shares